117 related articles for article (PubMed ID: 12096169)
1. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine.
Fuller MA; Shermock KM; Secic M; Laich JS; Durkin MB
Psychiatr Serv; 2002 Jul; 53(7):855-60. PubMed ID: 12096169
[TBL] [Abstract][Full Text] [Related]
2. Cost evaluation of risperidone compared with olanzapine.
Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J
Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
[TBL] [Abstract][Full Text] [Related]
3. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
[TBL] [Abstract][Full Text] [Related]
4. Use of atypical antipsychotics in a Veterans Affairs hospital.
Schwartz TL; Saba M; Hardoby W; Virk S; Masand PS
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1207-10. PubMed ID: 12452548
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
6. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
Zhao Z
Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
[TBL] [Abstract][Full Text] [Related]
7. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
8. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals.
Voris JC; Glazer WM
Psychiatr Serv; 1999 Feb; 50(2):163-4, 168. PubMed ID: 10030472
[No Abstract] [Full Text] [Related]
9. [RODOS: risperidone olanzapine drug outcome studies in schizophrenia].
De Beauchamp I; Giraud-Baro E; Gury C
Encephale; 2002; 28 Spec No 2 Pt 2():S33-4. PubMed ID: 12587356
[No Abstract] [Full Text] [Related]
10. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
[TBL] [Abstract][Full Text] [Related]
11. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
12. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
13. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
Ren XS; Kazis LE; Lee AF; Huang YH; Hamed A; Cunningham F; Herz L; Miller DR
Schizophr Res; 2005 Sep; 77(2-3):167-77. PubMed ID: 15894460
[TBL] [Abstract][Full Text] [Related]
14. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
Zhao Z
Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
[TBL] [Abstract][Full Text] [Related]
16. Health care costs for schizophrenia patients started on olanzapine versus risperidone.
Russo PA; Smith MW; Namjoshi M
Am J Health Syst Pharm; 2005 Mar; 62(6):610-5. PubMed ID: 15757882
[TBL] [Abstract][Full Text] [Related]
17. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
Kelly DL; Nelson MW; Love RC; Yu Y; Conley RR
Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
Palmer CS; Brunner E; Ruíz-Flores LG; Paez-Agraz F; Revicki DA
Arch Med Res; 2002; 33(6):572-80. PubMed ID: 12505105
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]